ストックスクリーナーアプリを入手
1.09
3.54%
-0.04
Lisata Therapeutics Inc (LSTA) 最新ニュース
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – FWB:8NE - TradingView
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – SWB:8NE - TradingView
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics (8NE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - Kalkine
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingView
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com India
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce - Investing.com
Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value - marketscreener.com
Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Ter - GuruFocus
Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco - Minichart
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees - marketscreener.com
Lisata Therapeutics terminates Dr. Kristen K. Buck as EVP R&D & CMO; James Nisco awarded $200,000 retention bonus - TradingView
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Proactive financial news
Lisata sues Kuva Labs after merger deal ends, c... - pluang.com
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lisata Therapeutics (LSTA) Terminates Merger Agreement with Kuva Labs Amid Financing Issues - GuruFocus
LSTA|Lisata Therapeutics Inc|Price:1.470|Chg%:-0.200 - TradingKey
Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Cash Flow - TradingKey
Lisata Therapeutics Inc (LSTA) Institutional Confidence - TradingKey
TradingKey - TradingKey
Lisata Therapeutics (LSTA) Plunges 21%: Key Levels to WatchZero Gamma Level - po-news-eg.net
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review - The Globe and Mail
Lisata Therapeutics, Inc. Revenue Breakdown – LS:A3DWGC - TradingView
Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal - Moomoo
Lisata Therapeutics Terminates Merger Agreement With Kuva Labs On July 24, Says SEC Filing - TradingView
Lisata Therapeutics Stock Falls After Hours: Here's Why - webull.com
Lisata Therapeutics Inc (LSTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lisata Therapeutics (LSTA) says Kuva tender meets conditions but financing not yet secured - Stock Titan
Kuva Labs, Inc. completed the acquisition of Lisata Therapeutics, Inc.. - marketscreener.com
Lisata Therapeutics (LSTA) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics Amends Merger Agreement with Kuva Labs—Key Details from Latest 8-K Filing - Minichart
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics Extends Merger Timeline with Kuva Labs - TipRanks
Lisata Therapeutics, Kuva Labs Amend Merger Agreement to Extend Outside Date to July 21 - TradingView
Lisata (Nasdaq: LSTA) merger timeline with Kuva pushed to July 21 - Stock Titan
Lisata Therapeutics (LSTA) extends Kuva tender offer as 64.7% of shares tendered - Stock Titan
Lisata Therapeutics (LSTA) tender offer extended as Kuva reports 64.67% tendered - Stock Titan
Lisata Therapeutics (LSTA) extends $4 cash-plus-CVR tender to July 16 - Stock Titan
Lisata Therapeutics (LSTA) Edges Higher: Navigating Support and Resistance LevelsSystematic Flow - dars.gov.et
Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Price to sales forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Enterprise value to revenue forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Price to earnings forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Price to earnings forward of Lisata Therapeutics, Inc. – LSX:A3DWGC - TradingView
Lisata Therapeutics (LSTA) Sees Modest Uptick as Stock Tests Resistance Near $3.52Donchian Channel - po-news-eg.net
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com Nigeria
Lisata Therapeutics (LSTA) amends 14D-9, restates $4.00 cash offer plus CVR - Stock Titan
Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE) - TradingView
LSTA Forecast — Price Target — Prediction for 2027 - TradingView
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing - GlobeNewswire
Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA) - TradingView
Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lisata Therapeutics (LSTA) Stalls at $3.47 as Stock Hovers Between Key Support and Resistance LevelsStrong Buy Stocks - DonanımHaber
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):